The Board of Directors of Liberty Biopharma Inc. announced the appointment of veteran technology executive Peter Ashkin as an independent director. Mr. Ashkin's appointment expands the Board to five directors, three of whom are independent. Mr. Ashkin will be a member of both the company's audit committee and its compensation and corporate governance committee. The appointment is subject to regulatory approval including that of the TSX Venture Exchange.